|  Sign up!  


Return to Course Listing



CME: Acute Lymphoblastic Leukemia (ALL): Highlights from the 2015 American Society of Hematology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation


Program Description / Statement of Need:

In this online CME self-learning program:


Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners.  The 2015 American Society of Hematology Annual Meeting & Exposition (ASH 2015) is no exception.  Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting. 


Acute Lymphoblastic Leukemia:


Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.  The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.These symptoms include: fatigue, malaise, or palpitations associated with anemia; fever with or without infection due to leukopenia or leukocytosis; and petechiae, and bleeding or bruising of the oral mucosa, skin, or gastrointestinal tract due to thrombocytopenia.  Although the precise etiology of ALL remains unknown, some cases have been associated with: exposure to ionizing, toxic chemicals, herbicides; genetic conditions such as Down’s syndrome, Fanconi syndrome, neurofibromatosis; viruses like human T-lymphotropic viruses 1 and 2 and Epstein-Barr virus.  After clinical suspicion is aroused, diagnostics include: a complete blood count, bone marrow biopsy, and flow cytometry.





Faculty member introduction, disclosures

Major findings from ASH 2015, including clinical trial data  relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)

Application: patient cases

Summary, conclusion, and best practice recap






Target Audience:

Hematologist-oncologists, medical oncologists, oncology nurse practitioners, physician assistants who specialize in oncology, and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with ALL.

Program Objectives:

By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
    • Additional objectives to be dictated by clinical content


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.


    Credit Designation: ScientiaCME designates this educational activity for a maximum of  1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.




    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-16-005-H01-P.  ACPE Accreditation effective 5/15/16, expires 5/15/18. 

    This is a Knowledge (K)-type activity.

    Release Date: May 15, 2016
    Expiration Date: May 15, 2018

    Faculty: Dan Douer MD

    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


    Faculty Disclosure:  Dan Douer, MD has received financial compensation from participation at advisory boards and/or research grants from Amgen and Baxalta.


    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.


    Commercial Support Disclosure: This program is supported by educational grants from Baxalta and AMGEN.

    Additional Courses That Are Related To This Course

    Acute Lymphoblastic Leukemia (ALL): Highlights from the 2015 American Society of Clinical Oncology (ASCO)

    Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society for Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

    Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

    Adult Acute Lymphoblastic Leukemia (ALL) in Adults: 2015 Overview


    Viewing Instructions



    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by educational grants from Baxalta and AMGEN.


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.